Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Gilead Sciences

Status: Completed

Conditions: Chronic Lymphocytic Leukaemia

Treatments: Drug: Idelalisib; Drug: Rituximab

Study type: Observational

Funder types: Industry

Identifiers

NCT03582098

GS-UK-312-4639

Details and patient eligibility

About

The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting

Enrollment: 112 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of CLL documented within medical records
• Individuals who have received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation at the time of starting idelalisib treatment
• Idelalisib and rituximab initiated on or before 31 December 2017

Exclusion criteria

• Individuals who received idelalisib as part of an interventional clinical trial
• Individuals who received idelalisib for other indications including follicular lymphoma (FL)
• Individuals who previously received idelalisib in combination with ofatumumab
• Use of idelalisib which is not in accordance with its marketing authorisation at the time of starting idelalisib treatment

Trial design

112 participants in 1 patient group

Idelalisib and Rituximab

Description:

Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.

Treatment:

Drug: Idelalisib

Drug: Rituximab